Bortezomib for refractory antibody-mediated cardiac allograft rejection.
This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.
Department of Medicine, University of Minnesota, USA.
Peter M
PM
Eckman
Marit
M
Thorsgard
David
D
Maurer
Youngki
Y
Kim
Rita R
RR
Alloway
E Steve
ES
Woodle
D000368:Aged; D001706:Biopsy; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D009202:Cardiomyopathies / Q000235:genetics / Q000601:surgery*; D005260:Female; D005434:Flow Cytometry; D006084:Graft Rejection / Q000188:drug therapy*; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
D001897:Boronic Acids; D007518:Isoantibodies; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib